MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamanetworkopen.2025.17056

Медицинская библиотека · JAMA network open · 2025

Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.

Joyce Daniel D, Wymer Kevin M, Graves John A, Boorjian Stephen A, Gore John L, Khaki Ali Raza, Raldow Ann C, Williams Stephen B, Smith Angela B, Sharma Vidit

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

IMPORTANCE

Trimodal therapy (TMT) is included as an alternative to radical cystectomy (RC) for definitive management of muscle-invasive bladder cancer (MIBC) in current clinical guidelines. Moreover, a 2023 retrospective analysis reported similar oncologic outcomes between these treatments among patients deemed fit for RC. Data regarding the comparative value of these treatments are lacking.

OBJECTIVE

To evaluate the comparative cost-effectiveness of TMT and RC for treatment of MIBC.

DESIGN, SETTING, AND

PARTICIPANTS

This economic evaluation compared cost-effectiveness of treatments using a health transition state microsimulation model of patients with bladder cancer treated between 2005 and 2017 with 5- and 10-year horizons from a Medicare perspective. Model probabilities were informed by multicenter retrospective analyses published in 2023 comparing TMT with RC. The index patient was aged 71 years, with clinical stage T2-4aN0M0 MIBC, solitary tumor smaller than 7 cm, no or unilateral hydronephrosis, adequate bladder function, and lack of multifocal or extensive carcinoma in situ. Patients unfit for RC, radiation, or cisplatin-based chemotherapy were excluded.

EXPOSURES: TMT and RC.

MAIN OUTCOME AND MEASURES: Primary outcomes included effectiveness measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICER) using a willingness-to-pay threshold of $100 000 per QALY. Sensitivity analyses were performed to assess the robustness of the model.

RESULTS

For the index patient, at 5 years, the average cost was $30 525 higher for TMT than RC. Average QALYs were 3.87 and 3.94 for RC and TMT, respectively. As such, TMT was not cost-effective at 5-year (ICER, $464 291 per QALY) or 10-year (ICER, $308 638 per QALY) time horizons. On 1-way sensitivity analyses, TMT would become cost-effective if (1) TMT costs were less than $17 605; or (2) TMT resulted in an 11.6% improvement in metastasis-free survival relative to RC.

CONCLUSIONS AND RELEVANCE: In this economic evaluation study of TMT and RC for treatment of MIBC, TMT was associated with improved quality of life but was not cost-effective relative to RC at 5 and 10 years given higher treatment costs. These findings highlight the importance of developing policy initiatives that help reduce TMT costs and of providing patients with accurate expectations of long-term toxic effects to help guide preference-sensitive care.

Для цитирования: Joyce Daniel D, Wymer Kevin M, Graves John A, Boorjian Stephen A, Gore John L, Khaki Ali Raza, Raldow Ann C, Williams Stephen B, Smith Angela B, Sharma Vidit. Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.. JAMA network open. 2025. DOI: 10.1001/jamanetworkopen.2025.17056.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.